Literature DB >> 7578393

Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice.

D Lew1, S E Parker, T Latimer, A M Abai, A Kuwahara-Rundell, S G Doh, Z Y Yang, D Laface, S H Gromkowski, G J Nabel.   

Abstract

The fate of plasmid DNA complexed with cationic lipids delivered intravenously in mice was evaluated at selected timepoints up to 6 months postinjection. Blood half-life and tissue distribution of plasmid DNA and potential expression in tissues were examined. Southern blot analyses of blood indicated that intact plasmid DNA was rapidly degraded, with a half-life of less than 5 min for intact plasmid, and was no longer detectable at 1 hr postinjection. Southern analyses of tissue demonstrated that intact DNA was differentially retained in the lung, spleen, liver, heart, kidney, marrow, and muscle up to 24 hr postinjection. After 7 days, no intact plasmid DNA was detectable by Southern blot analysis; however, the plasmid was detectable by the polymerase chain reaction (PCR) in all tissues examined at 7 and 28 days postinjection. At 6 months postinjection, femtogram levels of plasmid were detected only in muscle. Immunohistochemical analyses did not detect encoded protein in the tissues harboring residual plasmid at 1 or 7 days postinjection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578393     DOI: 10.1089/hum.1995.6.5-553

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  24 in total

Review 1.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 2.  Electroporation of the vasculature and the lung.

Authors:  David A Dean
Journal:  DNA Cell Biol       Date:  2003-12       Impact factor: 3.311

3.  Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells.

Authors:  Samantha Jilek; Michael Ulrich; Hans P Merkle; Elke Walter
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

Review 4.  Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview.

Authors:  Zinnia P Parra-Guillén; Gloria González-Aseguinolaza; Pedro Berraondo; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2010-04-13       Impact factor: 4.200

5.  Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy.

Authors:  I Y Chen; O Gheysens; S Ray; Q Wang; P Padmanabhan; R Paulmurugan; A M Loening; M Rodriguez-Porcel; J K Willmann; A Y Sheikh; C H Nielsen; G Hoyt; C H Contag; R C Robbins; S Biswal; J C Wu; S S Gambhir
Journal:  Gene Ther       Date:  2010-03-18       Impact factor: 5.250

6.  In vivo kinetics and biodistribution of a Hantaan virus DNA vaccine after intramuscular injection in mice.

Authors:  Si Wang; Qing Nie; Lan-yan Zheng; Jun Hu; En-jie Luo
Journal:  Virol Sin       Date:  2010-06-06       Impact factor: 4.327

7.  Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.

Authors:  K Jooss; Y Yang; K J Fisher; J M Wilson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

8.  Distinct domains of adenovirus E1A interact with specific cellular factors to differentially modulate human immunodeficiency virus transcription.

Authors:  S F Parker; L K Felzien; N D Perkins; M J Imperiale; G J Nabel
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

Review 9.  Pharmaceutical approach to somatic gene therapy.

Authors:  F D Ledley
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

Review 10.  Bioreducible polycations as shuttles for therapeutic nucleic acid and protein transfection.

Authors:  Philipp M Klein; Ernst Wagner
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.